2017 Section 7 Green Book

PPIs and H2RAs Usage and Survival in HNSCC Patients

Table 1. Sociodemographic and clinicopathologic characteristics of the HNSCC cohort

Numerical measure

Mean (SD), median

Range

Age, y

57.9 years (11.2), 57 years

21 – 92

Categorical measures

n (%)

Gender Male

448 (75%) 148 (25%)

Female

Primary tumor subsite OC

150 (25%) 251 (42%) 135 (23%) 58 (10%)

OP

LA, HP

Other

Stage

Early (CIS, I, II)

110 (19%) 482 (81%)

Late (III, IV)

T stage 0,1,2

244 (41%) 305 (52%)

3,4 X,x

44 (7%)

Smoking Never

145 (24%) 226 (38%) 223 (38%)

Former (quit > 1 month)

Current (quit within 1 month) Race European American/white

560 (94%)

Non-white

34 (6%)

Married, Yes/No Married

369 (62%) 223 (38%)

Not married

Education

HS or less

236 (44%) 305 (56%)

Some college or more

Treatment

Surgery-only Radiation-only

68 (11%) 31 (5%) 75 (13%) 246 (41%) 176 (30%)

Surgery þ radiation Radiation þ chemotherapy Radiation, chemotherapy, and surgery

NOTE: The study included 596 previously untreated patients with HNSCC that were enrolled in the epidemiology program of the University of Michigan Head and Neck Cancer Specialized Program of Excellence in Research (SPORE) from 2003 – 2008. The International Classi fi cation of Diseases for Oncology (ICD-9 codes) based on the Union for International Cancer Control (UICC) standard classi fi cation criteria for head and neck tumors were used. Pct may not add to 100% due to rounding. Abbreviations: CIS: carcinoma in situ ; HP, hypopharynx; HS: high school; LA, larynx; NP: nasopharynx; OC, oral cavity; OP, oropharynx; X, unknown.

in multivariate analysis after controlling for HPV16 [ P ¼ 0.03; HR (95% CI) ¼ 0.34 (0.12–0.92)]. Clinical significance of PPI usage Our analysis of PPI usage identified 327 patients who received PPI within 2 years of diagnosis of HNSCC (55% of

status. In the whole cohort of patients, we did not find evidence of a benefit of H2RA use for recurrence-free survival. Interestingly, subset analysis of the patients with oropha- ryngeal carcinomas and available HPV16 status indicated H2RA usage as prognostic for better recurrence-free survival

www.aacrjournals.org

Cancer Prev Res; 7(12) December 2014

191